Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

NCT00258258 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Withdrawn due to low accrual

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG: paricalcitol
DRUG: zoledronic acid

Sponsor

Roswell Park Cancer Institute